ACAD at a glance
ACADIA PHARMACEUTICALS INC (ACAD, SEC CIK 1070494) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 24, 2026 and Form 4 insider filings as recently as August 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ACADIA PHARMACEUTICALS INC (ACAD) reported revenue of $1.1 billion (up 11.9% from FY2024) and net income of $391.0 million. Diluted EPS was $2.30.
- As of June 30, 2026, 34 institutional investment managers tracked by SignalX reported holding ACADIA PHARMACEUTICALS INC (ACAD) shares worth $1.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Schneyer Mark C. on August 6, 2026 of 9,292 shares at $29.34 per share.
- In the last 90 days, ACAD insiders reported 0 open-market purchases ($0) and 5 open-market sales ($1.0M) on Form 4, a net sale of $1.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.1B
- +11.9% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$1.0M
- 13F holders
- 34 funds
- $1.7B · +0 vs prior quarter
- Latest 8-K
- Sep 24, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Cybersecurity incident escalation to audit committee requiring coordination among CIDO, Chief Legal Officer, and Senior VP of Finance
- New CIDO hired August 2025 tasked with integrating cybersecurity risk into overall risk strategy
- Senior Director of Info Security with decade-long company tenure leads cybersecurity risk management processes
- Incident response includes cross-functional senior management team and security operations integration
- Governance oversight involves regular audit committee reviews of cybersecurity threats and mitigation efforts
Management Discussion & Analysis
- Revenue $1,071.5M in 2025 vs $957.8M in 2024, driven by NUPLAZID and DAYBUE sales, up $113.7M YoY
- Operating loss driven by R&D expenses $328.8M in 2025 vs $303.2M in 2024; gross-to-net adjustments reduced net sales by $20.1M from Medicare rebate revision
- Best performing: DAYBUE, contributing significantly with expanded approvals; worst: ACP-101 discontinued post Phase 3 failure
- Cash inflows included $146.5M Rare Pediatric Disease PRV sale in 2024; capital outlays include $12M upfront and milestone payments in R&D for 2025
- Forward outlook notes substantial R&D investments continuing for remlifanserin and early-stage candidates; risks include regulatory milestone uncertainties and potential clinical trial delays
Business Overview
- Core business: biopharmaceutical focus on neurological and rare diseases with $1.07B net sales from NUPLAZID and DAYBUE in 2025, up from $958M in 2024
- New product launch: DAYBUE STIX powder formulation introduced in Q1 2026 for Rett syndrome, offering dosing flexibility and improved patient experience
- Strategic shift: expanding global footprint with EMA marketing authorization application and re-examination request after negative CHMP vote for trofinetide in Rett syndrome
- Quantitative highlight: initiated three Phase 2 studies in 2025-2026; remlifanserin for ADP and LBDP, ACP-211 for MDD, and planned ACP-711 Phase 2 start for essential tremor
- Noteworthy fact: discontinued development of ACP-101 after Phase 3 failure in Prader-Willi syndrome, refocusing resources on neurological and rare disease pipeline
AI summary of the ACAD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly product revenue $308.0M, up $43.4M from $264.6M YoY
- DAYBUE products strongest growth: $124.8M vs $96.1M YoY, up $28.7M
- NUPLAZID revenue $183.2M vs $168.5M YoY, up $14.7M
- Cost margin 91% vs 92% YoY, with cost of sales $28.3M vs $20.7M
- R&D $81.6M vs $78.0M; SG&A $160.3M vs $133.5M, driven by commercial investments
Risk Factors
- EU HTA Regulation effective January 12, 2025, creating evolving evidence requirements and potential reimbursement delays
- DAYBUE post-marketing obligations: FDA released one of five PMRs and three fulfilled, with remaining studies potentially prompting label changes
- NUPLAZID commercialization exposed to boxed-warning perceptions and FDA concerns over prescribing patterns
- Limited specialty-distributor and pharmacy network creating near-term product-access and profitability risk
- Future financing needs could constrain research, development, commercial and manufacturing efforts if capital remains unavailable
AI summary of the ACAD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD and generally excluded from Section 18 “filed” liability
- Exhibit not incorporated by reference into other Securities Act or Exchange Act filings absent specific reference
Item EX-99.1: Item EX-99.1
- Phase 2 primary endpoint narrowly missed: SAPS-H+D change -12.6 vs -10.4 placebo, p=0.0603
- Key secondary CGI-S-ADP favored 60 mg: change -1.3 vs -0.9 placebo, nominal p=0.0077
Item 8.01: Other Events
- 60 mg remlifanserin improved SAPS-H+D versus placebo at week 6, but primary endpoint missed nominal significance: p=0.0603
- CGI-S-ADP favored 60 mg, effect size 0.37 with nominal p=0.0077
Item 8.01: Other Events
- Court preliminary approval of derivative-action settlement in Kanner et al. v. Biggar et al.
- ACADIA required to publish settlement notice and stipulation under the Court’s order
Item EX-99.1: Item EX-99.1
- Proposed derivative settlement requires governance reforms maintained for at least four years
- Defendants to pay $1.5 million in attorneys’ fees and expenses, subject to court approval
Item 2.02: Results of Operations and Financial Condition
- Six-month financial results through June 30, 2026 announced on August 4, 2026
- Detailed results and management commentary furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $308M, up 16%; DAYBUE $125M rose 30%, while NUPLAZID $183M increased 9% GAAP
- 2026 revenue guidance raised to $1.24–$1.30B, with DAYBUE guidance increased to $480–$510M
AI summaries of ACAD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ACAD
Don't miss the next ACAD filing
- Alerts as it files. A push when ACAD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ACAD, by share count.
- Ask anything. An AI agent that reads every ACAD filing and answers with sources.
ACAD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Schneyer Mark C. | M | Aug 6, 2026 | 14,292 | - |
| Schneyer Mark C. | M | Aug 6, 2026 | 14,292 | $17.84 |
| Schneyer Mark C. | Sell | Aug 6, 2026 | 9,292 | $29.34 |
| Schneyer Mark C. | Sell | Aug 6, 2026 | 5,000 | $29.00 |
| Schneyer Mark C. | M | Aug 5, 2026 | 5,849 | - |
| Schneyer Mark C. | M | Aug 5, 2026 | 5,849 | $17.84 |
| Schneyer Mark C. | Sell | Aug 5, 2026 | 5,849 | $29.00 |
| Thompson Elizabeth H.Z. | Sell | Jul 30, 2026 | 50 | $26.17 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $957.8M | $1.1B |
| Operating Income | -$73.4M | $230.8M | $104.8M |
| Net Income | - | $226.5M | $391.0M |
| Op. Margin | - | 24.1% | 9.8% |
| Net Margin | - | 23.6% | 36.5% |
| Balance Sheet | |||
| Total Assets | $749.0M | $1.2B | $1.6B |
| Equity | $431.8M | $732.8M | $1.2B |
| ROE | - | 30.9% | 31.9% |
| Per Share | |||
| EPS | - | $1.36 | $2.30 |
| Cash Flow | |||
| Operating CF | - | $157.7M | $109.8M |
| CapEx | $50K | $523K | $4.7M |
Source: XBRL data in ACADIA PHARMACEUTICALS INC (ACAD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ACAD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 34 | $1.72B |
| Q1 2026 | 34 | $1.41B |
| Q4 2025 | 30 | $1.70B |
| Q3 2025 | 31 | $1.41B |
| Q2 2025 | 30 | $1.45B |
| Q1 2025 | 27 | $706.7M |
| Q4 2024 | 22 | $569.4M |
| Q3 2024 | 18 | $271.8M |
- Citadel Advisors LLC+1.56M (+250%)
- Goldman Sachs Group+1.02M (+66%)
- D.E. Shaw & Co+968.1K (+133%)
- BlackRock+964.3K (+4%)
- State Street Corp+743.4K (+9%)
- Renaissance Technologies LLC−441.6K (-26%)
- T. Rowe Price Group−427.6K (-67%)
- Bank of America Corp−253.4K (-16%)
- Morgan Stanley−146.5K (-13%)
- Millennium Management−115.5K (-16%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 226 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ACAD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 8-K | Sep 11, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Aug 7, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 8-K | May 29, 2026 | - | Analysis | |
| 4 | May 27, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| 8-K | May 1, 2026 | - | Analysis | - |
| SC 13G | Apr 28, 2026 | - | - | |
| 4 | Apr 7, 2026 | - | - | - |
| 4 | Apr 7, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ACAD SEC filings: frequently asked questions
Are ACAD insiders buying or selling?
In the last 90 days, ACADIA PHARMACEUTICALS INC (ACAD) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $1.0 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ACAD stock?
As of June 30, 2026, the largest ACADIA PHARMACEUTICALS INC (ACAD) holders among the 13F filers tracked by SignalX were BlackRock ($569.6 million), State Street Corp ($229.6 million), Vanguard Portfolio Management LLC ($223.6 million), Vanguard Capital Management LLC ($145.8 million), Dimensional Fund Advisors ($93.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ACAD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ACADIA PHARMACEUTICALS INC (ACAD) reported revenue of $1.1 billion (up 11.9% from FY2024) and net income of $391.0 million. Diluted EPS was $2.30. The figures come from the XBRL data in the 10-K.
What are the main risks in ACAD's latest 10-K?
In the 10-K filed February 26, 2026, ACADIA PHARMACEUTICALS INC (ACAD) flagged: Cybersecurity incident escalation to audit committee requiring coordination among CIDO, Chief Legal Officer, and Senior VP of Finance. New CIDO hired August 2025 tasked with integrating cybersecurity risk into overall risk strategy. (AI summary of the Risk Factors section.)
What did ACAD report in its latest 8-K?
ACADIA PHARMACEUTICALS INC (ACAD) filed an 8-K on September 24, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Exhibit 99.1 furnished under Regulation FD and generally excluded from Section 18 “filed” liability.
What are the latest ACAD SEC filings?
ACADIA PHARMACEUTICALS INC (ACAD) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 24, 2026 and a Form 4 insider filing on August 7, 2026.
What is ACAD's SEC CIK number?
ACADIA PHARMACEUTICALS INC (ACAD)'s SEC Central Index Key (CIK) is 1070494. EDGAR lists every ACAD filing under that number.
Ask anything about ACAD
The research agent reads ACAD's filings, financials, insider trades and 13F holders, then answers with sources.